Injectable controlled release depots for large molecules
Biodegradable, injectable depot formulations for long-term controlled drug release have improved therapy for a number of drug molecules and led to over a dozen highly successful pharmaceutical products. Until now, success has been limited to several small molecules and peptides, although remarkable...
Uložené v:
| Vydané v: | Journal of controlled release Ročník 190; s. 240 - 253 |
|---|---|
| Hlavní autori: | , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Netherlands
28.09.2014
|
| Predmet: | |
| ISSN: | 0168-3659, 1873-4995, 1873-4995 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Biodegradable, injectable depot formulations for long-term controlled drug release have improved therapy for a number of drug molecules and led to over a dozen highly successful pharmaceutical products. Until now, success has been limited to several small molecules and peptides, although remarkable improvements have been accomplished in some of these cases. For example, twice-a-year depot injections with leuprolide are available compared to the once-a-day injection of the solution dosage form. Injectable depots are typically prepared by encapsulation of the drug in poly(lactic-co-glycolic acid) (PLGA), a polymer that is used in children every day as a resorbable suture material, and therefore, highly biocompatible. PLGAs remain today as one of the few "real world" biodegradable synthetic biomaterials used in US FDA-approved parenteral long-acting-release (LAR) products. Despite their success, there remain critical barriers to the more widespread use of PLGA LARproducts, particularly for delivery of more peptides and other large molecular drugs, namely proteins. In this review, we describe key concepts in the development of injectable PLGA controlled-release depots for peptides and proteins, and then use this information to identify key issues impeding greater widespread use of PLGA depots for this class of drugs. Finally, we examine important approaches, particularly those developed in our research laboratory, toward overcoming these barriers to advance commercial LAR development. |
|---|---|
| AbstractList | Biodegradable, injectable depot formulations for long-term controlled drug release have improved therapy for a number of drug molecules and led to over a dozen highly successful pharmaceutical products. Until now, success has been limited to several small molecules and peptides, although remarkable improvements have been accomplished in some of these cases. For example, twice-a-year depot injections with leuprolide are available compared to the once-a-day injection of the solution dosage form. Injectable depots are typically prepared by encapsulation of the drug in poly(lactic-co-glycolic acid) (PLGA), a polymer that is used in children every day as a resorbable suture material, and therefore, highly biocompatible. PLGAs remain today as one of the few “real world” biodegradable synthetic biomaterials used in US FDA-approved parenteral long-acting-release (LAR) products. Despite their success, there remain critical barriers to the more widespread use of PLGA LARproducts, particularly for delivery of more peptides and other large molecular drugs, namely proteins. In this review, we describe key concepts in the development of injectable PLGA controlled-release depots for peptides and proteins, and then use this information to identify key issues impeding greater widespread use of PLGA depots for this class of drugs. Finally, we examine important approaches, particularly those developed in our research laboratory, toward overcoming these barriers to advance commercial LAR development. Biodegradable, injectable depot formulations for long-term controlled drug release have improved therapy for a number of drug molecules and led to over a dozen highly successful pharmaceutical products. Until now, success has been limited to several small molecules and peptides, although remarkable improvements have been accomplished in some of these cases. For example, twice-a-year depot injections with leuprolide are available compared to the once-a-day injection of the solution dosage form. Injectable depots are typically prepared by encapsulation of the drug in poly(lactic-co-glycolic acid) (PLGA), a polymer that is used in children every day as a resorbable suture material, and therefore, highly biocompatible. PLGAs remain today as one of the few “real world” biodegradable synthetic biomaterials used in US FDA-approved parenteral long-acting-release (LAR) products. Despite their success, there remain critical barriers to the more widespread use of PLGA LAR products, particularly for delivery of more peptides and other large molecular drugs, namely proteins. In this review, we describe key concepts in the development of injectable PLGA controlled-release depots for peptides and proteins, and then use this information to identify key issues impeding greater widespread use of PLGA depots for this class of drugs. Finally, we examine important approaches, particularly those developed in our research laboratory, toward overcoming these barriers to advance commercial LAR development. Biodegradable, injectable depot formulations for long-term controlled drug release have improved therapy for a number of drug molecules and led to over a dozen highly successful pharmaceutical products. Until now, success has been limited to several small molecules and peptides, although remarkable improvements have been accomplished in some of these cases. For example, twice-a-year depot injections with leuprolide are available compared to the once-a-day injection of the solution dosage form. Injectable depots are typically prepared by encapsulation of the drug in poly(lactic-co-glycolic acid) (PLGA), a polymer that is used in children every day as a resorbable suture material, and therefore, highly biocompatible. PLGAs remain today as one of the few "real world" biodegradable synthetic biomaterials used in US FDA-approved parenteral long-acting-release (LAR) products. Despite their success, there remain critical barriers to the more widespread use of PLGA LARproducts, particularly for delivery of more peptides and other large molecular drugs, namely proteins. In this review, we describe key concepts in the development of injectable PLGA controlled-release depots for peptides and proteins, and then use this information to identify key issues impeding greater widespread use of PLGA depots for this class of drugs. Finally, we examine important approaches, particularly those developed in our research laboratory, toward overcoming these barriers to advance commercial LAR development.Biodegradable, injectable depot formulations for long-term controlled drug release have improved therapy for a number of drug molecules and led to over a dozen highly successful pharmaceutical products. Until now, success has been limited to several small molecules and peptides, although remarkable improvements have been accomplished in some of these cases. For example, twice-a-year depot injections with leuprolide are available compared to the once-a-day injection of the solution dosage form. Injectable depots are typically prepared by encapsulation of the drug in poly(lactic-co-glycolic acid) (PLGA), a polymer that is used in children every day as a resorbable suture material, and therefore, highly biocompatible. PLGAs remain today as one of the few "real world" biodegradable synthetic biomaterials used in US FDA-approved parenteral long-acting-release (LAR) products. Despite their success, there remain critical barriers to the more widespread use of PLGA LARproducts, particularly for delivery of more peptides and other large molecular drugs, namely proteins. In this review, we describe key concepts in the development of injectable PLGA controlled-release depots for peptides and proteins, and then use this information to identify key issues impeding greater widespread use of PLGA depots for this class of drugs. Finally, we examine important approaches, particularly those developed in our research laboratory, toward overcoming these barriers to advance commercial LAR development. |
| Author | Schwendeman, Anna S. Shah, Ronak B. Schwendeman, Steven P. Bailey, Brittany A. |
| AuthorAffiliation | c Department of Medicinal Chemistry, The Biointerfaces Institute, North Campus Research Complex, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109, USA b Department of Biomedical Engineering, The Biointerfaces Institute, North Campus Research Complex, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109, USA a Department of Pharmaceutical Sciences, The Biointerfaces Institute, North Campus Research Complex, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109, US |
| AuthorAffiliation_xml | – name: b Department of Biomedical Engineering, The Biointerfaces Institute, North Campus Research Complex, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109, USA – name: c Department of Medicinal Chemistry, The Biointerfaces Institute, North Campus Research Complex, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109, USA – name: a Department of Pharmaceutical Sciences, The Biointerfaces Institute, North Campus Research Complex, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109, US |
| Author_xml | – sequence: 1 givenname: Steven P. surname: Schwendeman fullname: Schwendeman, Steven P. – sequence: 2 givenname: Ronak B. surname: Shah fullname: Shah, Ronak B. – sequence: 3 givenname: Brittany A. surname: Bailey fullname: Bailey, Brittany A. – sequence: 4 givenname: Anna S. surname: Schwendeman fullname: Schwendeman, Anna S. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24929039$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUU1r3DAUFGFDstn2J7T42Is3T5ZlWRQCJeQLFnJJzkKWnlIbrbWVvIH8-2jZTWh7SHgP3kEzo2HmjMzGMCIh3ygsKdDmfFgOJowR_bICWi-B5xVHZE5bwcpaSj4j84xrS9ZweUrOUhoAgLNanJDTqpaVBCbnpL0bBzST7jwWWW-KwXu0RdZFnbCwuAlTKlyIhdfxCYt18Gi2HtMXcuy0T_j1cBfk8frq4fK2XN3f3F3-WpWmFmIqtUCNnW6dlFJQho5b0QEYJiRrW2iw7Yxj4Ay2trO17aquoUxbB8wxZoEtyMVed7Pt1mgNZo_aq03s1zq-qKB79e_L2P9WT-FZ1VVDqdwJ_DgIxPBni2lS6z4Z9F6PGLZJVTlOxrgU_FMobUAyaPJk6Pe_bb37eUs2A37uASaGlCI6ZfpJT_0uY917RUHtelSDOvSodj0q4HlFZvP_2G8ffMx7BReTpm4 |
| CitedBy_id | crossref_primary_10_1016_j_jconrel_2014_08_029 crossref_primary_10_1016_j_actbio_2019_03_014 crossref_primary_10_1016_j_ejpb_2017_04_002 crossref_primary_10_1007_s13346_025_01806_y crossref_primary_10_1016_j_jconrel_2023_02_024 crossref_primary_10_1016_j_ijpharm_2022_121875 crossref_primary_10_1016_j_addr_2021_04_006 crossref_primary_10_1002_adhm_201400608 crossref_primary_10_3389_fbioe_2017_00024 crossref_primary_10_1007_s11095_022_03391_y crossref_primary_10_3390_antiox11040686 crossref_primary_10_1016_j_biomaterials_2021_120823 crossref_primary_10_1016_j_colsurfb_2022_112834 crossref_primary_10_1002_adfm_201502819 crossref_primary_10_1016_j_jddst_2018_09_004 crossref_primary_10_1021_acs_chemrev_4c00989 crossref_primary_10_1016_j_ijpharm_2020_119964 crossref_primary_10_1038_s41467_017_01114_1 crossref_primary_10_1002_mabi_201700307 crossref_primary_10_1016_j_ijpharm_2020_119441 crossref_primary_10_1109_JERM_2022_3149685 crossref_primary_10_1016_j_jconrel_2015_06_025 crossref_primary_10_1016_j_ejpb_2015_06_008 crossref_primary_10_1016_j_ijpharm_2022_121889 crossref_primary_10_1016_j_jconrel_2021_06_044 crossref_primary_10_4155_tde_2020_0113 crossref_primary_10_1016_j_ejps_2019_105165 crossref_primary_10_1080_17460441_2017_1317243 crossref_primary_10_3390_pharmaceutics10030130 crossref_primary_10_1016_j_jconrel_2020_02_005 crossref_primary_10_1007_s13346_024_01747_y crossref_primary_10_1007_s11095_020_02825_9 crossref_primary_10_1016_j_supflu_2017_06_002 crossref_primary_10_2217_nnm_15_146 crossref_primary_10_1016_j_ijpharm_2021_120926 crossref_primary_10_1016_j_ijpharm_2021_120807 crossref_primary_10_1016_j_ijpharm_2025_125340 crossref_primary_10_1080_14760584_2023_2229431 crossref_primary_10_1016_j_ejpb_2021_04_004 crossref_primary_10_1016_j_ijpharm_2024_123836 crossref_primary_10_1016_j_jconrel_2015_06_039 crossref_primary_10_1016_j_ijpharm_2015_08_063 crossref_primary_10_1016_j_jconrel_2021_12_010 crossref_primary_10_1080_10717544_2022_2069882 crossref_primary_10_1016_j_addr_2022_114401 crossref_primary_10_1016_j_jconrel_2015_09_001 crossref_primary_10_1016_j_jconrel_2019_12_039 crossref_primary_10_3390_pharmaceutics17040529 crossref_primary_10_1016_j_jconrel_2019_05_003 crossref_primary_10_3390_pharmaceutics17050626 crossref_primary_10_1016_j_addr_2020_10_004 crossref_primary_10_1208_s12248_019_0405_z crossref_primary_10_1016_j_xphs_2019_02_012 crossref_primary_10_1039_D2BM01519F crossref_primary_10_3390_pharmaceutics12060510 crossref_primary_10_1208_s12248_017_0128_y crossref_primary_10_1002_pen_25508 crossref_primary_10_1016_j_colsurfb_2017_08_027 crossref_primary_10_1016_j_ejps_2018_02_019 crossref_primary_10_1038_s41467_022_30813_7 crossref_primary_10_1016_j_jconrel_2016_11_032 crossref_primary_10_3389_fnins_2020_00785 crossref_primary_10_1016_j_jconrel_2021_12_017 crossref_primary_10_1016_j_jddst_2023_104529 crossref_primary_10_1016_j_colsurfb_2018_09_072 crossref_primary_10_1016_j_ijpharm_2023_122731 crossref_primary_10_1016_j_ijpharm_2018_01_026 crossref_primary_10_1016_j_ijpharm_2025_125917 crossref_primary_10_1002_adfm_202409796 crossref_primary_10_1016_j_ejpb_2017_02_011 crossref_primary_10_1007_s00203_024_03910_y crossref_primary_10_2174_0115748855270864240104094025 crossref_primary_10_1016_j_ijpharm_2017_05_069 crossref_primary_10_1016_j_jconrel_2023_09_015 crossref_primary_10_1080_17425247_2022_2105318 crossref_primary_10_1038_s41598_019_53356_2 crossref_primary_10_1038_s41551_017_0078 crossref_primary_10_1016_j_ijpharm_2025_126176 crossref_primary_10_1016_j_jconrel_2017_03_009 crossref_primary_10_1007_s42114_022_00467_6 crossref_primary_10_1093_ejcts_ezv025 crossref_primary_10_1002_btm2_10272 crossref_primary_10_1016_j_ijpharm_2023_123213 crossref_primary_10_1016_j_colsurfb_2018_04_063 crossref_primary_10_1016_j_ijpharm_2015_12_025 crossref_primary_10_1002_smll_202104971 crossref_primary_10_1134_S1990793119070078 crossref_primary_10_1016_j_ijpharm_2019_05_070 crossref_primary_10_1016_j_bbrc_2018_05_063 crossref_primary_10_1016_j_jconrel_2020_01_023 crossref_primary_10_1007_s11095_015_1731_1 crossref_primary_10_1208_s12249_020_01878_8 crossref_primary_10_1016_j_ijpharm_2019_01_061 crossref_primary_10_1016_j_xphs_2018_05_003 crossref_primary_10_1016_j_xphs_2024_01_004 crossref_primary_10_1016_j_jpba_2017_08_046 crossref_primary_10_1002_wnan_1516 crossref_primary_10_1016_j_actbio_2017_06_013 crossref_primary_10_1038_s41551_021_00698_w crossref_primary_10_3390_pharmaceutics12070683 crossref_primary_10_1093_rb_rbae146 crossref_primary_10_1208_s12248_023_00864_9 crossref_primary_10_1016_j_ijpharm_2018_07_013 crossref_primary_10_1016_j_jconrel_2017_05_035 crossref_primary_10_1007_s11095_020_2757_6 crossref_primary_10_1007_s13346_024_01577_y crossref_primary_10_1016_j_ejps_2022_106253 crossref_primary_10_1016_j_jconrel_2019_03_002 crossref_primary_10_1016_j_ijpharm_2021_120329 crossref_primary_10_1016_j_jconrel_2025_113743 crossref_primary_10_1016_j_jconrel_2015_05_198 crossref_primary_10_1134_S1990793120070027 crossref_primary_10_1007_s13346_023_01349_0 crossref_primary_10_1016_j_biomaterials_2024_122594 crossref_primary_10_1016_j_addr_2016_06_018 crossref_primary_10_1007_s13346_023_01424_6 crossref_primary_10_1016_j_jconrel_2019_04_039 crossref_primary_10_1016_j_ijpharm_2023_123517 crossref_primary_10_3390_pharmaceutics12040311 crossref_primary_10_1016_j_jconrel_2023_06_016 crossref_primary_10_1208_s12249_023_02705_6 crossref_primary_10_1016_j_ijpharm_2018_03_043 crossref_primary_10_2174_0124522716306759240522112102 crossref_primary_10_1016_j_jddst_2022_103609 crossref_primary_10_4155_tde_15_71 crossref_primary_10_1016_j_ijpharm_2024_123991 crossref_primary_10_1007_s10439_022_03109_6 crossref_primary_10_1080_14656566_2016_1258058 crossref_primary_10_1016_j_ijpharm_2025_126083 crossref_primary_10_1002_jcph_1842 crossref_primary_10_1007_s13346_022_01143_4 crossref_primary_10_1016_j_ejps_2024_106704 crossref_primary_10_1016_j_jconrel_2017_07_012 crossref_primary_10_1016_j_jconrel_2020_01_028 crossref_primary_10_1016_j_ejpb_2021_11_007 crossref_primary_10_1016_j_cclet_2023_108250 crossref_primary_10_1016_j_jconrel_2023_06_029 crossref_primary_10_1016_j_bioadv_2025_214230 crossref_primary_10_1080_10837450_2021_1944207 crossref_primary_10_1371_journal_pone_0107408 crossref_primary_10_3390_biomedicines8120589 crossref_primary_10_1016_j_ijpharm_2024_124334 crossref_primary_10_1016_j_jconrel_2016_08_023 crossref_primary_10_1016_j_addr_2018_07_009 crossref_primary_10_1007_s00289_022_04623_2 crossref_primary_10_1016_j_ijpharm_2020_119707 crossref_primary_10_1016_j_jddst_2020_102206 |
| Cites_doi | 10.1002/jps.10414 10.1002/jcp.1041380129 10.1586/14737140.5.4.605 10.1038/nrd3365 10.1002/jps.1106 10.1016/0142-9612(96)89664-5 10.1007/s11095-011-0517-3 10.1038/71916 10.1038/nbt0298-153 10.1089/dia.2011.0050 10.1002/jps.20512 10.1002/anie.201206387 10.1002/bit.20481 10.1016/j.ijpharm.2007.02.026 10.1016/S0090-4295(02)02396-8 10.1021/mp200608y 10.1021/mp800027f 10.1021/ma0481959 10.1016/j.jconrel.2012.04.022 10.1016/j.jconrel.2013.06.035 10.1002/adem.201080088 10.1016/S0168-3659(98)00173-4 10.2165/11585880-000000000-00000 10.1021/mp060041n 10.1038/sj.pcan.4500778 10.1517/17425247.5.6.615 10.1007/s10147-010-0095-0 10.1016/0168-3659(94)00011-5 10.1023/A:1018901619230 10.1517/17425240802680169 10.1007/s11095-009-9914-2 10.1016/j.jconrel.2012.10.012 10.1023/A:1011009117586 10.1023/A:1007582911958 10.1210/jc.2013-1437 10.1016/0142-9612(81)90059-4 10.1007/s11095-008-9594-3 10.1039/b711716g 10.1016/S0378-5173(02)00187-4 10.1002/smll.200801855 10.1007/s11095-013-1019-2 10.1016/j.reactfunctpolym.2010.10.002 10.1016/S0168-3659(98)00061-3 10.1016/j.jconrel.2006.02.004 10.1038/nm0796-795 10.1080/08990220600700925 10.1016/j.addr.2004.09.002 10.1210/en.2009-1431 10.1016/S0168-3659(02)00137-2 10.1023/A:1012142204132 10.1016/0168-3659(95)00125-5 10.1089/jir.2007.0073 10.1023/A:1011939607573 10.1021/bc700442g 10.1016/j.addr.2012.10.003 10.1038/453840a 10.1038/nrd1033 10.1021/ja055287k 10.1016/j.progpolymsci.2007.05.017 10.1023/A:1018822002353 10.1016/j.jconrel.2007.03.014 10.1615/CritRevTherDrugCarrierSyst.v19.i1.20 10.1016/S0304-4165(98)00097-X 10.1016/j.progpolymsci.2010.04.002 10.1023/A:1007513425337 10.1177/0145721709345773 10.1211/0022357021778448 10.1038/71875 10.1038/nature02388 10.1177/193229680700100517 10.1016/j.copbio.2007.09.008 10.1146/annurev-chembioeng-073009-100847 10.1007/s11095-005-2589-4 10.1007/s11095-006-0180-2 10.2337/dc09-1914 10.1016/j.clinthera.2009.12.014 10.1023/A:1026498209874 10.1016/j.jconrel.2009.03.006 10.1021/bm901409k 10.1007/s00216-004-2771-2 10.1016/S0168-3659(98)00030-3 10.1002/mabi.201300323 10.1016/j.ejps.2011.09.006 10.1016/j.jconrel.2004.07.029 10.1007/BF02324706 10.1002/jps.20625 10.1007/BF02980037 10.1002/jps.10524 10.1016/j.jconrel.2013.08.295 10.1016/j.jconrel.2005.02.020 10.1016/S0168-3659(02)00165-7 10.1615/CritRevTherDrugCarrierSyst.v12.i1.10 10.1016/j.ijpharm.2003.11.021 10.1002/jps.20243 10.1016/S0168-3659(98)00140-0 10.1016/S1367-5931(00)00227-1 10.1016/S0142-9612(01)00101-6 10.1177/193229680800200325 10.1016/S0168-3659(01)00248-6 10.1517/17425247.2.1.29 10.1007/BF00647204 |
| ContentType | Journal Article |
| Copyright | Copyright © 2014 Elsevier B.V. All rights reserved. 2014 Elsevier B.V. All rights reserved. 2014 |
| Copyright_xml | – notice: Copyright © 2014 Elsevier B.V. All rights reserved. – notice: 2014 Elsevier B.V. All rights reserved. 2014 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 5PM |
| DOI | 10.1016/j.jconrel.2014.05.057 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-4995 |
| EndPage | 253 |
| ExternalDocumentID | PMC4261190 24929039 10_1016_j_jconrel_2014_05_057 |
| Genre | Research Support, U.S. Gov't, P.H.S Review Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL 68345 – fundername: FDA HHS grantid: U01 FD005014 – fundername: NIBIB NIH HHS grantid: R21 EB008873 – fundername: FDA HHS grantid: U01 FD 005014 – fundername: NHLBI NIH HHS grantid: R01 HL068345 – fundername: NIBIB NIH HHS grantid: R21 EB 08873 |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9DU 9JM AABNK AABXZ AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO AAYXX ABFNM ABFRF ABJNI ABMAC ABOCM ABWVN ABXDB ABZDS ACDAQ ACGFO ACGFS ACIUM ACLOT ACNNM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEZYN AFJKZ AFPUW AFRZQ AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CITATION CS3 D-I DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W KOM M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RNS ROL RPZ SCC SDF SDG SDP SES SEW SPC SPCBC SPT SSM SSP SSZ T5K TEORI WUQ ~G- ~HD AGCQF AGRNS CGR CUY CVF ECM EIF NPM RIG SSH 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c477t-a7eaeba8f999713ef5d7b00c37938806e8bcf30fce8dbd4db2b613adf03f33d03 |
| ISICitedReferencesCount | 170 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000345910900012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0168-3659 1873-4995 |
| IngestDate | Tue Sep 30 16:52:48 EDT 2025 Sun Sep 28 11:54:37 EDT 2025 Sun Sep 28 01:14:56 EDT 2025 Mon Jul 21 05:58:28 EDT 2025 Sat Nov 29 06:13:11 EST 2025 Tue Nov 18 22:42:59 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Depot Biodegradable PLGA Peptide Controlled release Protein |
| Language | English |
| License | Copyright © 2014 Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c477t-a7eaeba8f999713ef5d7b00c37938806e8bcf30fce8dbd4db2b613adf03f33d03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://doi.org/10.1016/j.jconrel.2014.05.057 |
| PMID | 24929039 |
| PQID | 1609306060 |
| PQPubID | 23479 |
| PageCount | 14 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4261190 proquest_miscellaneous_2101335975 proquest_miscellaneous_1609306060 pubmed_primary_24929039 crossref_citationtrail_10_1016_j_jconrel_2014_05_057 crossref_primary_10_1016_j_jconrel_2014_05_057 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-09-28 |
| PublicationDateYYYYMMDD | 2014-09-28 |
| PublicationDate_xml | – month: 09 year: 2014 text: 2014-09-28 day: 28 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Journal of controlled release |
| PublicationTitleAlternate | J Control Release |
| PublicationYear | 2014 |
| References | Woodruff (10.1016/j.jconrel.2014.05.057_bb0360) 2010; 35 Hutchinson (10.1016/j.jconrel.2014.05.057_bb0065) 1982 Allison (10.1016/j.jconrel.2014.05.057_bb0080) 2008; 5 Gopferich (10.1016/j.jconrel.2014.05.057_bb0420) 1994; 11 Arendt-Nielsen (10.1016/j.jconrel.2014.05.057_bb0280) 2006; 23 Rouse (10.1016/j.jconrel.2014.05.057_bb0235) 2007; 339 Ding (10.1016/j.jconrel.2014.05.057_bb0530) 2006; 128 Kang (10.1016/j.jconrel.2014.05.057_bb0095) 2006; 4 Kim (10.1016/j.jconrel.2014.05.057_bb0370) 2010; 11 Butler (10.1016/j.jconrel.2014.05.057_bb0195) 1999; 58 Jiang (10.1016/j.jconrel.2014.05.057_bb0040) 2011; 10 Kinoshita (10.1016/j.jconrel.2014.05.057_bb0290) 2010; 15 Wang (10.1016/j.jconrel.2014.05.057_bb0090) 2002; 82 Ramstack (10.1016/j.jconrel.2014.05.057_bb0610) 2003 Montgomery (10.1016/j.jconrel.2014.05.057_bb0295) 2005; 8 Ding (10.1016/j.jconrel.2014.05.057_bb0550) 2008; 25 Zhou (10.1016/j.jconrel.2014.05.057_bb0020) 1998; 55 Xu (10.1016/j.jconrel.2014.05.057_bb0605) 2009; 5 Desai (10.1016/j.jconrel.2014.05.057_bb0465) 2013; 165 (10.1016/j.jconrel.2014.05.057_bb0265) 2013 Park (10.1016/j.jconrel.2014.05.057_bb0640) 2011; 71 (10.1016/j.jconrel.2014.05.057_bb0250) 2013 Heinemann (10.1016/j.jconrel.2014.05.057_bb0630) 2008; 2 Volkin (10.1016/j.jconrel.2014.05.057_bb0185) 1989 Sophocleous (10.1016/j.jconrel.2014.05.057_bb0655) 2009; 137 Kontermann (10.1016/j.jconrel.2014.05.057_bb0615) 2012 Zhang (10.1016/j.jconrel.2014.05.057_bb0560) 2012; 162 Mader (10.1016/j.jconrel.2014.05.057_bb0510) 1998; 15 Brunner (10.1016/j.jconrel.2014.05.057_bb0515) 1999; 16 Schwendeman (10.1016/j.jconrel.2014.05.057_bb0135) 1996 Bouissou (10.1016/j.jconrel.2014.05.057_bb0395) 2006; 23 Na (10.1016/j.jconrel.2014.05.057_bb0205) 2005; 22 Yang (10.1016/j.jconrel.2014.05.057_bb0375) 2008; 19 DeYoung (10.1016/j.jconrel.2014.05.057_bb0255) 2011; 13 de Rio (10.1016/j.jconrel.2014.05.057_bb0355) 2013; 61 Li (10.1016/j.jconrel.2014.05.057_bb0545) 2005; 101 Sommer (10.1016/j.jconrel.2014.05.057_bb0485) 1989; 138 Zhu (10.1016/j.jconrel.2014.05.057_bb0015) 2000; 18 Tamber (10.1016/j.jconrel.2014.05.057_bb0165) 2005; 57 Alcock (10.1016/j.jconrel.2014.05.057_bb0435) 2002; 82 van der Walle (10.1016/j.jconrel.2014.05.057_bb0175) 2009; 6 Kang (10.1016/j.jconrel.2014.05.057_bb0480) 2002; 23 Fu (10.1016/j.jconrel.2014.05.057_bb0440) 2003; 92 Buchholz (10.1016/j.jconrel.2014.05.057_bb0245) 1996 Putney (10.1016/j.jconrel.2014.05.057_bb0140) 1998; 16 Langer (10.1016/j.jconrel.2014.05.057_bb0300) 2004; 428 Grund (10.1016/j.jconrel.2014.05.057_bb0320) 2011; 13 Kyekyoon (10.1016/j.jconrel.2014.05.057_bb0600) 2006 Sartor (10.1016/j.jconrel.2014.05.057_bb0260) 2003; 61 Yamamoto (10.1016/j.jconrel.2014.05.057_bb0225) 1989 Fares (10.1016/j.jconrel.2014.05.057_bb0620) 2010; 151 Wool (10.1016/j.jconrel.2014.05.057_bb0085) 2008; 4 Nair (10.1016/j.jconrel.2014.05.057_bb0330) 2007; 32 Mazzara (10.1016/j.jconrel.2014.05.057_bb0645) 2013; 171 Kissel (10.1016/j.jconrel.2014.05.057_bb0145) 1996 Hawkes (10.1016/j.jconrel.2014.05.057_bb0535) 1988; 25 Butler (10.1016/j.jconrel.2014.05.057_bb0380) 2008; 453 Gabizon (10.1016/j.jconrel.2014.05.057_bb0590) 2012; 45 Schwendeman (10.1016/j.jconrel.2014.05.057_bb0595) 2011 (10.1016/j.jconrel.2014.05.057_bb0035) 2014 Wright (10.1016/j.jconrel.2014.05.057_bb0650) 2013 Howard Bernstein (10.1016/j.jconrel.2014.05.057_bb0105) 2004 Luck (10.1016/j.jconrel.2014.05.057_bb0575) 1998; 55 Ghassemi (10.1016/j.jconrel.2014.05.057_bb0365) 2012; 29 (10.1016/j.jconrel.2014.05.057_bb0325) 2000; 752 Pérez (10.1016/j.jconrel.2014.05.057_bb0160) 2002; 54 Castellanos (10.1016/j.jconrel.2014.05.057_bb0580) 2005; 94 Reinhold (10.1016/j.jconrel.2014.05.057_bb0215) 2012; 51 Khossravi (10.1016/j.jconrel.2014.05.057_bb0230) 1993; 22 Gill (10.1016/j.jconrel.2014.05.057_bb0240) 2007; 1 Floyd (10.1016/j.jconrel.2014.05.057_bb0270) 1996 Zhu (10.1016/j.jconrel.2014.05.057_bb0110) 2000; 17 Pillai (10.1016/j.jconrel.2014.05.057_bb0305) 2001; 5 Xichen (10.1016/j.jconrel.2014.05.057_bb0130) 1994; 31 Fu (10.1016/j.jconrel.2014.05.057_bb0665) 2000; 17 Ding (10.1016/j.jconrel.2014.05.057_bb0500) 2004; 93 Fu (10.1016/j.jconrel.2014.05.057_bb0520) 2000; 17 van de Weert (10.1016/j.jconrel.2014.05.057_bb0150) 2000; 17 Zhang (10.1016/j.jconrel.2014.05.057_bb0555) 2009; 26 Kim (10.1016/j.jconrel.2014.05.057_bb0400) 2006; 112 Castellanos (10.1016/j.jconrel.2014.05.057_bb0445) 2006; 95 Viswanathan (10.1016/j.jconrel.2014.05.057_bb0415) 1999; 58 Long (10.1016/j.jconrel.2014.05.057_bb0345) 2010 Johansen (10.1016/j.jconrel.2014.05.057_bb0570) 1998; 1425 Brown (10.1016/j.jconrel.2014.05.057_bb0170) 2005; 2 Yuen (10.1016/j.jconrel.2014.05.057_bb0625) 2013; 98 Jiang (10.1016/j.jconrel.2014.05.057_bb0490) 2008; 5 Hiemstra (10.1016/j.jconrel.2014.05.057_bb0495) 2007; 119 Fu (10.1016/j.jconrel.2014.05.057_bb0180) 2000; 18 Yeo (10.1016/j.jconrel.2014.05.057_bb0075) 2004; 27 Jiang (10.1016/j.jconrel.2014.05.057_bb0115) 2001; 18 Jeyanthi (10.1016/j.jconrel.2014.05.057_bb0410) 1996; 38 Kamei (10.1016/j.jconrel.2014.05.057_bb0390) 1996 Okada (10.1016/j.jconrel.2014.05.057_bb0200) 1995; 12 Wang (10.1016/j.jconrel.2014.05.057_bb0430) 2005; 381 Johnson (10.1016/j.jconrel.2014.05.057_bb0460) 1997; 14 Mader (10.1016/j.jconrel.2014.05.057_bb0505) 1996; 17 Veldhuis (10.1016/j.jconrel.2014.05.057_bb0670) 2009; 9 Zhang (10.1016/j.jconrel.2014.05.057_bb0315) 2013; 65 Liechty (10.1016/j.jconrel.2014.05.057_bb0310) 2010; 1 (10.1016/j.jconrel.2014.05.057_bb0045) 2013 Buse (10.1016/j.jconrel.2014.05.057_bb0025) 2010; 33 (10.1016/j.jconrel.2014.05.057_bb0005) 2013 Daly (10.1016/j.jconrel.2014.05.057_bb0585) 2005; 90 (10.1016/j.jconrel.2014.05.057_bb0010) 2014 (10.1016/j.jconrel.2014.05.057_bb0050) 2014 Fineman (10.1016/j.jconrel.2014.05.057_bb0070) 2011; 50 Estey (10.1016/j.jconrel.2014.05.057_bb0475) 2006; 95 Husmann (10.1016/j.jconrel.2014.05.057_bb0100) 2002; 242 Harris (10.1016/j.jconrel.2014.05.057_bb0030) 2003; 2 Liu (10.1016/j.jconrel.2014.05.057_bb0190) 2012; 9 Reinhold (10.1016/j.jconrel.2014.05.057_bb0220) 2013; 13 Karp (10.1016/j.jconrel.2014.05.057_bb0335) 2007; 18 Langer (10.1016/j.jconrel.2014.05.057_bb0125) 1981; 2 Huang (10.1016/j.jconrel.2014.05.057_bb0450) 2001; 73 Shah (10.1016/j.jconrel.2014.05.057_bb0565) 2013 (10.1016/j.jconrel.2014.05.057_bb0635) 2014 Park (10.1016/j.jconrel.2014.05.057_bb0340) 2000; 752 De Leede (10.1016/j.jconrel.2014.05.057_bb0350) 2008; 28 Rubin (10.1016/j.jconrel.2014.05.057_bb0275) 2009; 35 Hinds (10.1016/j.jconrel.2014.05.057_bb0425) 2005; 104 Johnson (10.1016/j.jconrel.2014.05.057_bb0455) 1996; 2 Schwendeman (10.1016/j.jconrel.2014.05.057_bb0540) 2013 Schwendeman (10.1016/j.jconrel.2014.05.057_bb0155) 2002; 19 Jiang (10.1016/j.jconrel.2014.05.057_bb0120) 2001; 90 Sophocleous (10.1016/j.jconrel.2014.05.057_bb0210) 2013; 172 Shenderova (10.1016/j.jconrel.2014.05.057_bb0525) 2004; 37 Kim (10.1016/j.jconrel.2014.05.057_bb0385) 2014 (10.1016/j.jconrel.2014.05.057_bb0055) 2013 Cox (10.1016/j.jconrel.2014.05.057_bb0285) 2005; 5 Desai (10.1016/j.jconrel.2014.05.057_bb0470) 2013; 30 Fuchs (10.1016/j.jconrel.2014.05.057_bb0060) 2009; 31 Carmichael (10.1016/j.jconrel.2014.05.057_bb0660) 2010 Kim (10.1016/j.jconrel.2014.05.057_bb0405) 2004; 271 |
| References_xml | – volume: 92 start-page: 1582 year: 2003 ident: 10.1016/j.jconrel.2014.05.057_bb0440 article-title: A potential approach for decreasing the burst effect of protein from PLGA microspheres publication-title: J. Pharm. Sci. doi: 10.1002/jps.10414 – volume: 138 start-page: 215 year: 1989 ident: 10.1016/j.jconrel.2014.05.057_bb0485 article-title: Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan publication-title: J. Cell. Physiol. doi: 10.1002/jcp.1041380129 – volume: 5 start-page: 605 year: 2005 ident: 10.1016/j.jconrel.2014.05.057_bb0285 article-title: Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? publication-title: Expert. Rev. Anticancer. Ther. doi: 10.1586/14737140.5.4.605 – year: 2010 ident: 10.1016/j.jconrel.2014.05.057_bb0660 article-title: Why Don't More Medical Discoveries Become Cures? – volume: 10 start-page: 101 year: 2011 ident: 10.1016/j.jconrel.2014.05.057_bb0040 article-title: Advances in the assessment and control of the effector functions of therapeutic antibodies publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd3365 – year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0565 article-title: A biomimetic approach to active self-healing microencapsulation of proteins in PLGA, poster present – volume: 90 start-page: 1558 year: 2001 ident: 10.1016/j.jconrel.2014.05.057_bb0120 article-title: Stabilization of a model formalinized protein antigen encapsulated in poly(lactide-co-glycolide)-based microspheres publication-title: J. Pharm. Sci. doi: 10.1002/jps.1106 – volume: 17 start-page: 457 year: 1996 ident: 10.1016/j.jconrel.2014.05.057_bb0505 article-title: Non-invasive in vivo characterization of release processes in biodegradable polymers by low-frequency electron paramagnetic resonance spectroscopy publication-title: Biomaterials doi: 10.1016/0142-9612(96)89664-5 – volume: 29 start-page: 110 year: 2012 ident: 10.1016/j.jconrel.2014.05.057_bb0365 article-title: Controlled release of octreotide and assessment of peptide acylation from poly(d, l-lactide-co-hydroxymethyl glycolide) compared to PLGA microspheres publication-title: Pharm. Res. doi: 10.1007/s11095-011-0517-3 – year: 2011 ident: 10.1016/j.jconrel.2014.05.057_bb0595 – volume: 18 start-page: 52 year: 2000 ident: 10.1016/j.jconrel.2014.05.057_bb0015 article-title: Stabilization of proteins encapsulated in injectable poly(lactide-co-glycolide) publication-title: Nat. Biotechnol. doi: 10.1038/71916 – volume: 16 start-page: 153 year: 1998 ident: 10.1016/j.jconrel.2014.05.057_bb0140 article-title: Improving protein therapeutics with sustained-release formulations publication-title: Nat. Biotechnol. doi: 10.1038/nbt0298-153 – volume: 13 start-page: 1145 year: 2011 ident: 10.1016/j.jconrel.2014.05.057_bb0255 article-title: Encapsulation of exenatide in poly-(d,l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes publication-title: Diabetes Technol. Ther. doi: 10.1089/dia.2011.0050 – volume: 95 start-page: 849 year: 2006 ident: 10.1016/j.jconrel.2014.05.057_bb0445 article-title: Effect of cyclodextrins on alpha-chymotrypsin stability and loading in PLGA microspheres upon S/O/W encapsulation publication-title: J. Pharm. Sci. doi: 10.1002/jps.20512 – volume: 51 start-page: 10800 year: 2012 ident: 10.1016/j.jconrel.2014.05.057_bb0215 article-title: Self-healing microencapsulation of biomacromolecules without organic solvents publication-title: Angew. Chem. Int. Ed. doi: 10.1002/anie.201206387 – volume: 90 start-page: 856 year: 2005 ident: 10.1016/j.jconrel.2014.05.057_bb0585 article-title: Adsorption of poly(ethylene glycol)-modified ribonuclease A to a poly(lactide-co-glycolide) surface publication-title: Biotechnol. Bioeng. doi: 10.1002/bit.20481 – volume: 339 start-page: 112 year: 2007 ident: 10.1016/j.jconrel.2014.05.057_bb0235 article-title: Physical ageing and thermal analysis of PLGA microspheres encapsulating protein or DNA publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2007.02.026 – year: 2014 ident: 10.1016/j.jconrel.2014.05.057_bb0635 – volume: 61 start-page: 25 year: 2003 ident: 10.1016/j.jconrel.2014.05.057_bb0260 article-title: Eligard: leuprolide acetate in a novel sustained-release delivery system publication-title: Urology doi: 10.1016/S0090-4295(02)02396-8 – volume: 9 start-page: 1342 year: 2012 ident: 10.1016/j.jconrel.2014.05.057_bb0190 article-title: Mapping microclimate pH distribution inside protein- encapsulated PLGA microspheres using confocal laser scanning microscopy publication-title: Mol. Pharm. doi: 10.1021/mp200608y – year: 1996 ident: 10.1016/j.jconrel.2014.05.057_bb0270 article-title: Injectable emulsions and suspensions – volume: 5 start-page: 808 year: 2008 ident: 10.1016/j.jconrel.2014.05.057_bb0490 article-title: Stabilization of tetanus toxoid encapsulated in PLGA microspheres publication-title: Mol. Pharm. doi: 10.1021/mp800027f – volume: 752 start-page: 2 year: 2000 ident: 10.1016/j.jconrel.2014.05.057_bb0340 article-title: Controlled drug delivery: designing technologies for the future publication-title: Am. Chem. Soc. – year: 2003 ident: 10.1016/j.jconrel.2014.05.057_bb0610 – volume: 37 start-page: 10052 year: 2004 ident: 10.1016/j.jconrel.2014.05.057_bb0525 article-title: Potentiometric method for determination of microclimate pH in poly(lactic-co-glycolic acid) films publication-title: Macromolecules doi: 10.1021/ma0481959 – volume: 162 start-page: 119 year: 2012 ident: 10.1016/j.jconrel.2014.05.057_bb0560 article-title: Minimizing acylation of peptides in PLGA microspheres publication-title: J. Control. Release doi: 10.1016/j.jconrel.2012.04.022 – volume: 171 start-page: 172 year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0645 article-title: Healing kinetics of microneedle-formed pores in PLGA films publication-title: J. Control. Release doi: 10.1016/j.jconrel.2013.06.035 – volume: 13 start-page: B61 year: 2011 ident: 10.1016/j.jconrel.2014.05.057_bb0320 article-title: Polymers in drug delivery—state of the art and future trends publication-title: Adv. Eng. Mater. doi: 10.1002/adem.201080088 – volume: 58 start-page: 335 year: 1999 ident: 10.1016/j.jconrel.2014.05.057_bb0195 article-title: Adsorption of serum albumin to thin films of poly(lactide-co-glycolide) publication-title: J. Control. Release doi: 10.1016/S0168-3659(98)00173-4 – volume: 50 start-page: 65 year: 2011 ident: 10.1016/j.jconrel.2014.05.057_bb0070 article-title: Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing publication-title: Clin. Pharmacokinet. doi: 10.2165/11585880-000000000-00000 – year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0005 – volume: 4 start-page: 104 year: 2006 ident: 10.1016/j.jconrel.2014.05.057_bb0095 article-title: Pore closing and opening in biodegradable polymers and their effect on the controlled release of proteins publication-title: Mol. Pharm. doi: 10.1021/mp060041n – volume: 8 start-page: 66 year: 2005 ident: 10.1016/j.jconrel.2014.05.057_bb0295 article-title: Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection publication-title: Prostate Cancer Prostatic Dis. doi: 10.1038/sj.pcan.4500778 – volume: 5 start-page: 615 year: 2008 ident: 10.1016/j.jconrel.2014.05.057_bb0080 article-title: Analysis of initial burst in PLGA microparticles publication-title: Expert Opin. Drug Deliv. doi: 10.1517/17425247.5.6.615 – volume: 15 start-page: 472 year: 2010 ident: 10.1016/j.jconrel.2014.05.057_bb0290 article-title: Effectiveness of skin icing in reducing pain associated with goserelin acetate injection publication-title: Int. J. Clin. Oncol. doi: 10.1007/s10147-010-0095-0 – volume: 31 start-page: 129 year: 1994 ident: 10.1016/j.jconrel.2014.05.057_bb0130 article-title: A mechanistic study of antibiotic release from biodegradable poly(d,l-lactide) cylinders publication-title: J. Control. Release doi: 10.1016/0168-3659(94)00011-5 – start-page: 1 year: 1996 ident: 10.1016/j.jconrel.2014.05.057_bb0135 article-title: Stability of proteins and their delivery from biodegradable polymer microspheres – volume: 11 start-page: 1568 year: 1994 ident: 10.1016/j.jconrel.2014.05.057_bb0420 article-title: Development and characterization of microencapsulated microspheres publication-title: Pharm. Res. doi: 10.1023/A:1018901619230 – year: 1982 ident: 10.1016/j.jconrel.2014.05.057_bb0065 article-title: Continuous release pharmaceutical compositions – year: 2014 ident: 10.1016/j.jconrel.2014.05.057_bb0050 – volume: 6 start-page: 177 year: 2009 ident: 10.1016/j.jconrel.2014.05.057_bb0175 article-title: Current approaches to stabilising and analysing proteins during microencapsulation in PLGA publication-title: Expert Opin. Drug Deliv. doi: 10.1517/17425240802680169 – volume: 26 start-page: 1986 year: 2009 ident: 10.1016/j.jconrel.2014.05.057_bb0555 article-title: Inhibition of peptide acylation in PLGA microspheres with water-soluble divalent cationic salts publication-title: Pharm. Res. doi: 10.1007/s11095-009-9914-2 – volume: 165 start-page: 62 year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0465 article-title: Active self-healing encapsulation of vaccine antigens in PLGA microspheres publication-title: J. Control. Release doi: 10.1016/j.jconrel.2012.10.012 – volume: 18 start-page: 878 year: 2001 ident: 10.1016/j.jconrel.2014.05.057_bb0115 article-title: Stabilization and controlled release of bovine serum albumin encapsulated in poly(d, l-lactide) and poly(ethylene glycol) microsphere blends publication-title: Pharm. Res. doi: 10.1023/A:1011009117586 – year: 2010 ident: 10.1016/j.jconrel.2014.05.057_bb0345 – volume: 9 start-page: 24 year: 2009 ident: 10.1016/j.jconrel.2014.05.057_bb0670 article-title: Monodisperse microspheres for parenteral drug delivery publication-title: Drug Deliv. Technol. – volume: 17 start-page: 100 year: 2000 ident: 10.1016/j.jconrel.2014.05.057_bb0520 article-title: Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres publication-title: Pharm. Res. doi: 10.1023/A:1007582911958 – volume: 98 start-page: 2595 year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0625 article-title: A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo- controlled, single ascending dose study in growth hormone-deficient adults publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2013-1437 – volume: 2 start-page: 201 year: 1981 ident: 10.1016/j.jconrel.2014.05.057_bb0125 article-title: Present and future applications of biomaterials in controlled drug delivery systems publication-title: Biomaterials doi: 10.1016/0142-9612(81)90059-4 – volume: 25 start-page: 2041 year: 2008 ident: 10.1016/j.jconrel.2014.05.057_bb0550 article-title: Acidic microclimate pH distribution in PLGA microspheres monitored by confocal laser scanning microscopy publication-title: Pharm. Res. doi: 10.1007/s11095-008-9594-3 – year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0265 – volume: 4 start-page: 400 year: 2008 ident: 10.1016/j.jconrel.2014.05.057_bb0085 article-title: Self-healing materials: a review publication-title: Soft Matter doi: 10.1039/b711716g – volume: 242 start-page: 277 year: 2002 ident: 10.1016/j.jconrel.2014.05.057_bb0100 article-title: Polymer erosion in PLGA microparticles produced by phase separation method publication-title: Int. J. Pharm. doi: 10.1016/S0378-5173(02)00187-4 – volume: 61 year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0355 article-title: VASOMERATM, a novel vpac2-selective vasoactive intestinal peptide agonist, enhances contractility and decreases myocardial demand in dogs with both normal hearts and with pacing-induced dilated cardiomyopathy publication-title: J. Am. Coll. Cardiol. – volume: 5 start-page: 1575 year: 2009 ident: 10.1016/j.jconrel.2014.05.057_bb0605 article-title: Preparation of monodisperse biodegradable polymer microparticles using a microfluidic flow-focusing device for controlled drug delivery publication-title: Small doi: 10.1002/smll.200801855 – year: 2012 ident: 10.1016/j.jconrel.2014.05.057_bb0615 – volume: 30 start-page: 1768 year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0470 article-title: Gamma irradiation of active self-healing PLGA microspheres for efficient aqueous encapsulation of vaccine antigens publication-title: Pharm. Res. doi: 10.1007/s11095-013-1019-2 – volume: 71 start-page: 280 year: 2011 ident: 10.1016/j.jconrel.2014.05.057_bb0640 article-title: Oral protein delivery: current status and future prospect publication-title: React. Funct. Polym. doi: 10.1016/j.reactfunctpolym.2010.10.002 – volume: 55 start-page: 281 year: 1998 ident: 10.1016/j.jconrel.2014.05.057_bb0020 article-title: Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy publication-title: J. Control. Release doi: 10.1016/S0168-3659(98)00061-3 – year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0055 – volume: 112 start-page: 167 year: 2006 ident: 10.1016/j.jconrel.2014.05.057_bb0400 article-title: Biodegradable polymeric microspheres with “open/closed” pores for sustained release of human growth hormone publication-title: J. Control. Release doi: 10.1016/j.jconrel.2006.02.004 – volume: 2 start-page: 795 year: 1996 ident: 10.1016/j.jconrel.2014.05.057_bb0455 article-title: A month-long effect from a single injection of microencapsulated human growth hormone publication-title: Nat. Med. doi: 10.1038/nm0796-795 – volume: 23 start-page: 37 year: 2006 ident: 10.1016/j.jconrel.2014.05.057_bb0280 article-title: Pain following controlled cutaneous insertion of needles with different diameters publication-title: Somatosens. Mot. Res. doi: 10.1080/08990220600700925 – volume: 57 start-page: 357 year: 2005 ident: 10.1016/j.jconrel.2014.05.057_bb0165 article-title: Formulation aspects of biodegradable polymeric microspheres for antigen delivery publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2004.09.002 – volume: 151 start-page: 4410 year: 2010 ident: 10.1016/j.jconrel.2014.05.057_bb0620 article-title: Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH publication-title: Endocrinology doi: 10.1210/en.2009-1431 – volume: 82 start-page: 289 year: 2002 ident: 10.1016/j.jconrel.2014.05.057_bb0090 article-title: Characterization of the initial burst release of a model peptide from poly(d, l-lactide-co-glycolide) microspheres publication-title: J. Control. Release doi: 10.1016/S0168-3659(02)00137-2 – volume: 14 start-page: 730 year: 1997 ident: 10.1016/j.jconrel.2014.05.057_bb0460 article-title: The stabilization and encapsulation of human growth hormone into biodegradable microspheres publication-title: Pharm. Res. doi: 10.1023/A:1012142204132 – volume: 38 start-page: 235 year: 1996 ident: 10.1016/j.jconrel.2014.05.057_bb0410 article-title: Effect of solvent removal technique on the matrix characteristics of polylactide/glycolide microspheres for peptide delivery publication-title: J. Control. Release doi: 10.1016/0168-3659(95)00125-5 – volume: 28 start-page: 113 year: 2008 ident: 10.1016/j.jconrel.2014.05.057_bb0350 article-title: Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial publication-title: J. Interf. Cytokine Res. doi: 10.1089/jir.2007.0073 – start-page: 51 year: 1996 ident: 10.1016/j.jconrel.2014.05.057_bb0145 article-title: Injectable biodegradable microspheres for vaccine delivery – volume: 15 start-page: 787 year: 1998 ident: 10.1016/j.jconrel.2014.05.057_bb0510 publication-title: Pharm. Res. doi: 10.1023/A:1011939607573 – volume: 19 start-page: 1164 year: 2008 ident: 10.1016/j.jconrel.2014.05.057_bb0375 article-title: Polyketal copolymers: A new acid-sensitive delivery vehicle for treating acute inflammatory diseases publication-title: Bioconjug. Chem. doi: 10.1021/bc700442g – volume: 65 start-page: 104 year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0315 article-title: Advanced materials and processing for drug delivery: the past and the future publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2012.10.003 – volume: 453 start-page: 840 year: 2008 ident: 10.1016/j.jconrel.2014.05.057_bb0380 article-title: Translational research: crossing the valley of death publication-title: Nature doi: 10.1038/453840a – volume: 2 start-page: 214 year: 2003 ident: 10.1016/j.jconrel.2014.05.057_bb0030 article-title: Effect of pegylation on pharmaceuticals publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd1033 – volume: 128 start-page: 5384 year: 2006 ident: 10.1016/j.jconrel.2014.05.057_bb0530 article-title: Prediction of microclimate pH in poly(lactic-co-glycolic acid) films publication-title: J. Am. Chem. Soc. doi: 10.1021/ja055287k – volume: 32 start-page: 762 year: 2007 ident: 10.1016/j.jconrel.2014.05.057_bb0330 article-title: Biodegradable polymers as biomaterials publication-title: Prog. Polym. Sci. doi: 10.1016/j.progpolymsci.2007.05.017 – volume: 16 start-page: 847 year: 1999 ident: 10.1016/j.jconrel.2014.05.057_bb0515 article-title: pH and osmotic pressure inside biodegradable microspheres during erosion publication-title: Pharm. Res. doi: 10.1023/A:1018822002353 – volume: 119 start-page: 320 year: 2007 ident: 10.1016/j.jconrel.2014.05.057_bb0495 article-title: In vitro and in vivo protein delivery from in situ forming poly(ethylene glycol)–poly(lactide) hydrogels publication-title: J. Control. Release doi: 10.1016/j.jconrel.2007.03.014 – volume: 19 start-page: 73 year: 2002 ident: 10.1016/j.jconrel.2014.05.057_bb0155 article-title: Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems publication-title: Crit. Rev. Ther. Drug Carrier Syst. doi: 10.1615/CritRevTherDrugCarrierSyst.v19.i1.20 – volume: 1425 start-page: 425 year: 1998 ident: 10.1016/j.jconrel.2014.05.057_bb0570 article-title: Physico-chemical and antigenic properties of tetanus and diphtheria toxoids and steps towards improved stability publication-title: Biochim. Biophys. Acta doi: 10.1016/S0304-4165(98)00097-X – volume: 35 start-page: 1217 year: 2010 ident: 10.1016/j.jconrel.2014.05.057_bb0360 article-title: The return of a forgotten polymer—polycaprolactone in the 21st century publication-title: Prog. Polym. Sci. doi: 10.1016/j.progpolymsci.2010.04.002 – volume: 17 start-page: 351 year: 2000 ident: 10.1016/j.jconrel.2014.05.057_bb0110 article-title: Stabilization of proteins encapsulated in cylindrical poly(lactide-co-glycolide) implants: mechanism of stabilization by basic additives publication-title: Pharm. Res. doi: 10.1023/A:1007513425337 – volume: 35 start-page: 1014 year: 2009 ident: 10.1016/j.jconrel.2014.05.057_bb0275 article-title: Barriers to insulin injection therapy: patient and health care provider perspectives publication-title: Diabetes Educ. doi: 10.1177/0145721709345773 – year: 1989 ident: 10.1016/j.jconrel.2014.05.057_bb0225 – volume: 54 start-page: 301 year: 2002 ident: 10.1016/j.jconrel.2014.05.057_bb0160 article-title: Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers publication-title: J. Pharm. Pharmacol. doi: 10.1211/0022357021778448 – volume: 18 start-page: 24 year: 2000 ident: 10.1016/j.jconrel.2014.05.057_bb0180 article-title: Protein stability in controlled-release systems publication-title: Nat. Biotechnol. doi: 10.1038/71875 – year: 2014 ident: 10.1016/j.jconrel.2014.05.057_bb0035 – volume: 428 start-page: 487 year: 2004 ident: 10.1016/j.jconrel.2014.05.057_bb0300 article-title: Designing materials for biology and medicine publication-title: Nature doi: 10.1038/nature02388 – volume: 1 start-page: 725 year: 2007 ident: 10.1016/j.jconrel.2014.05.057_bb0240 article-title: Does needle size matter? publication-title: J. Diabetes Sci. Technol. doi: 10.1177/193229680700100517 – volume: 18 start-page: 454 year: 2007 ident: 10.1016/j.jconrel.2014.05.057_bb0335 article-title: Development and therapeutic applications of advanced biomaterials publication-title: Curr. Opin. Biotechnol. doi: 10.1016/j.copbio.2007.09.008 – year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0045 – volume: 1 start-page: 149 year: 2010 ident: 10.1016/j.jconrel.2014.05.057_bb0310 article-title: Polymers for drug delivery systems publication-title: Annu. Rev. Chem. Biomol. doi: 10.1146/annurev-chembioeng-073009-100847 – volume: 22 start-page: 736 year: 2005 ident: 10.1016/j.jconrel.2014.05.057_bb0205 article-title: PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by poly(d,l-lactide-co-glycolide) publication-title: Pharm. Res. doi: 10.1007/s11095-005-2589-4 – volume: 752 start-page: 1 year: 2000 ident: 10.1016/j.jconrel.2014.05.057_bb0325 article-title: K. Park, R.J. Mrsny (Eds.), Controlled drug delivery: designing technologies for the future publication-title: Am. Chem. Soc. – volume: 23 start-page: 1295 year: 2006 ident: 10.1016/j.jconrel.2014.05.057_bb0395 article-title: The influence of surfactant on PLGA microsphere glass transition and water sorption: remodeling the surface morphology to attenuate the burst release publication-title: Pharm. Res. doi: 10.1007/s11095-006-0180-2 – volume: 33 start-page: 1255 year: 2010 ident: 10.1016/j.jconrel.2014.05.057_bb0025 article-title: DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks publication-title: Diabetes Care doi: 10.2337/dc09-1914 – year: 2006 ident: 10.1016/j.jconrel.2014.05.057_bb0600 – volume: 31 start-page: 2906 year: 2009 ident: 10.1016/j.jconrel.2014.05.057_bb0060 article-title: Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test publication-title: Clin. Ther. doi: 10.1016/j.clinthera.2009.12.014 – volume: 17 start-page: 1159 year: 2000 ident: 10.1016/j.jconrel.2014.05.057_bb0150 article-title: Protein instability in poly(lactic-co-glycolic acid) microparticles publication-title: Pharm. Res. doi: 10.1023/A:1026498209874 – volume: 137 start-page: 179 year: 2009 ident: 10.1016/j.jconrel.2014.05.057_bb0655 article-title: A new class of inhibitors of peptide sorption and acylation in PLGA publication-title: J. Control. Release doi: 10.1016/j.jconrel.2009.03.006 – volume: 11 start-page: 555 year: 2010 ident: 10.1016/j.jconrel.2014.05.057_bb0370 article-title: Polyoxalate nanoparticles as a biodegradable and biocompatible drug delivery vehicle publication-title: Biomacromolecules doi: 10.1021/bm901409k – volume: 381 start-page: 547 year: 2005 ident: 10.1016/j.jconrel.2014.05.057_bb0430 article-title: Bulk and surface modifications of polylactide publication-title: Anal. Bioanal. Chem. doi: 10.1007/s00216-004-2771-2 – volume: 55 start-page: 107 year: 1998 ident: 10.1016/j.jconrel.2014.05.057_bb0575 article-title: Plasma protein adsorption on biodegradable microspheres consisting of poly(d, l-lactide-co-glycolide), poly(l-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition publication-title: J. Control. Release doi: 10.1016/S0168-3659(98)00030-3 – volume: 13 start-page: 1700 year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0220 article-title: Effect of polymer porosity on aqueous self-healing encapsulation of proteins in PLGA microspheres publication-title: Macromol. Biosci. doi: 10.1002/mabi.201300323 – volume: 45 start-page: 388 year: 2012 ident: 10.1016/j.jconrel.2014.05.057_bb0590 article-title: Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2011.09.006 – volume: 101 start-page: 163 year: 2005 ident: 10.1016/j.jconrel.2014.05.057_bb0545 article-title: Mapping neutral microclimate pH in PLGA microspheres publication-title: J. Control. Release doi: 10.1016/j.jconrel.2004.07.029 – volume: 25 start-page: 313 year: 1988 ident: 10.1016/j.jconrel.2014.05.057_bb0535 article-title: Predicting retention data using the slope of the log adjusted retention time vs. carbon number plot for n-alkanes publication-title: Chromatographia doi: 10.1007/BF02324706 – year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0650 – year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0250 – volume: 95 start-page: 1626 year: 2006 ident: 10.1016/j.jconrel.2014.05.057_bb0475 article-title: BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems publication-title: J. Pharm. Sci. doi: 10.1002/jps.20625 – volume: 27 start-page: 1 year: 2004 ident: 10.1016/j.jconrel.2014.05.057_bb0075 article-title: Control of encapsulation efficiency and initial burst in polymeric microparticle systems publication-title: Arch. Pharm. Res. doi: 10.1007/BF02980037 – volume: 93 start-page: 322 year: 2004 ident: 10.1016/j.jconrel.2014.05.057_bb0500 article-title: Determination of water-soluble acid distribution in poly(lactide-co-glycolide) publication-title: J. Pharm. Sci. doi: 10.1002/jps.10524 – year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0540 article-title: Simulation of microclimate pH distribution and kinetics inside degrading PLGA microspheres, poster present – volume: 172 start-page: 662 year: 2013 ident: 10.1016/j.jconrel.2014.05.057_bb0210 article-title: The nature of peptide interactions with acid end-group PLGAs and facile aqueous-based microencapsulation of therapeutic peptides publication-title: J. Control. Release doi: 10.1016/j.jconrel.2013.08.295 – volume: 104 start-page: 447 year: 2005 ident: 10.1016/j.jconrel.2014.05.057_bb0425 article-title: PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis publication-title: J. Control. Release doi: 10.1016/j.jconrel.2005.02.020 – year: 1996 ident: 10.1016/j.jconrel.2014.05.057_bb0245 – volume: 82 start-page: 429 year: 2002 ident: 10.1016/j.jconrel.2014.05.057_bb0435 article-title: Modifying the release of leuprolide from spray dried OED microparticles publication-title: J. Control. Release doi: 10.1016/S0168-3659(02)00165-7 – volume: 12 start-page: 1 year: 1995 ident: 10.1016/j.jconrel.2014.05.057_bb0200 article-title: Biodegradable microspheres in drug delivery publication-title: Crit. Rev. Ther. Drug Carrier Syst. doi: 10.1615/CritRevTherDrugCarrierSyst.v12.i1.10 – volume: 271 start-page: 207 year: 2004 ident: 10.1016/j.jconrel.2014.05.057_bb0405 article-title: Critical effect of freezing/freeze-drying on sustained release of FITC-dextran encapsulated within PLGA microspheres publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2003.11.021 – volume: 94 start-page: 327 year: 2005 ident: 10.1016/j.jconrel.2014.05.057_bb0580 article-title: Effect of the covalent modification with poly(ethylene glycol) on alpha-chymotrypsin stability upon encapsulation in poly(lactic-co-glycolic) microspheres publication-title: J. Pharm. Sci. doi: 10.1002/jps.20243 – volume: 58 start-page: 9 year: 1999 ident: 10.1016/j.jconrel.2014.05.057_bb0415 article-title: Preparation of non-porous microspheres with high entrapment efficiency of proteins by a (water-in-oil)-in-oil emulsion technique publication-title: J. Control. Release doi: 10.1016/S0168-3659(98)00140-0 – volume: 5 start-page: 447 year: 2001 ident: 10.1016/j.jconrel.2014.05.057_bb0305 article-title: Polymers in drug delivery publication-title: Curr. Opin. Chem. Biol. doi: 10.1016/S1367-5931(00)00227-1 – volume: 23 start-page: 239 year: 2002 ident: 10.1016/j.jconrel.2014.05.057_bb0480 article-title: Comparison of the effects of Mg(OH)2 and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(d, l-lactide-co-glycolide) implants publication-title: Biomaterials doi: 10.1016/S0142-9612(01)00101-6 – volume: 2 start-page: 518 year: 2008 ident: 10.1016/j.jconrel.2014.05.057_bb0630 article-title: The failure of Exubera: are we beating a dead horse? publication-title: J. Diabetes Sci. Technol. doi: 10.1177/193229680800200325 – start-page: 1 year: 1989 ident: 10.1016/j.jconrel.2014.05.057_bb0185 article-title: Minimizing protein inactivation – year: 2004 ident: 10.1016/j.jconrel.2014.05.057_bb0105 – year: 2014 ident: 10.1016/j.jconrel.2014.05.057_bb0010 – volume: 17 start-page: 100 year: 2000 ident: 10.1016/j.jconrel.2014.05.057_bb0665 article-title: Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres publication-title: Pharm. Res. doi: 10.1023/A:1007582911958 – volume: 73 start-page: 121 year: 2001 ident: 10.1016/j.jconrel.2014.05.057_bb0450 article-title: On the importance and mechanisms of burst release in matrix-controlled drug delivery systems publication-title: J. Control. Release doi: 10.1016/S0168-3659(01)00248-6 – volume: 2 start-page: 29 year: 2005 ident: 10.1016/j.jconrel.2014.05.057_bb0170 article-title: Commercial challenges of protein drug delivery publication-title: Expert Opin. Drug Deliv. doi: 10.1517/17425247.2.1.29 – year: 1996 ident: 10.1016/j.jconrel.2014.05.057_bb0390 – year: 2014 ident: 10.1016/j.jconrel.2014.05.057_bb0385 – volume: 22 start-page: 321 year: 1993 ident: 10.1016/j.jconrel.2014.05.057_bb0230 article-title: Solvent effects on chemical processes. 3. Surface tension of binary aqueous organic solvents publication-title: J. Solution Chem. doi: 10.1007/BF00647204 |
| SSID | ssj0005347 |
| Score | 2.5455108 |
| SecondaryResourceType | review_article |
| Snippet | Biodegradable, injectable depot formulations for long-term controlled drug release have improved therapy for a number of drug molecules and led to over a dozen... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 240 |
| SubjectTerms | biocompatible materials Biocompatible Materials - administration & dosage biodegradability children Delayed-Action Preparations - administration & dosage Drug Carriers Drug Compounding drug delivery systems drug formulations drugs encapsulation Humans Injections Lactic Acid Macromolecular Substances - administration & dosage peptides Pharmacokinetics Polyglycolic Acid Polylactic Acid-Polyglycolic Acid Copolymer Polymers proteins United States |
| Title | Injectable controlled release depots for large molecules |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24929039 https://www.proquest.com/docview/1609306060 https://www.proquest.com/docview/2101335975 https://pubmed.ncbi.nlm.nih.gov/PMC4261190 |
| Volume | 190 |
| WOSCitedRecordID | wos000345910900012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-4995 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005347 issn: 0168-3659 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfYxgMviG_Kx2QktJctI62T2nksaIjxMFWiSH2LHNtR23VptWaw_ffc2U68rlTAA2oVVflwlPwu1_Pld78j5D1XkhWMJZHSqY6SUqpIZH3MiHFeCAixEx3bZhP87EyMx9nQEzJXtp0ArypxfZ0t_yvUsA7AxtLZf4C7HRRWwG8AHZYAOyz_CvjTClMrtiLK89DnRtveKPCHhczXRW01GA7nSAI_vHD9cT2VcDNM3RwjvLuZ_MQEepNDtf3RQr3Yt4mcOO52Jc9Dc-ePcurT5JiXqJFuMNgyIoo7-9Ssz0t0EyRR-Dpv43yp4CwCtNM1Z-uagzbu0kk1bbhxl1GYHc_gGuHakIGXWIFVJ2Z9C8XlhYURdQ-z2Mki3dHPbjbtkL0eTzPwfHuD05Px10AEYgkPtV0ffntW1Iz246wHMBuzkrvk2lvRyugReejxowNnHo_JPVM9IQdDp1N-c0RHoexudUQP6DAomN88JSLYEA34U48_dTZEwYaotSHa2tAz8v3zyejTl8i32IhUwnkdSW6kKaQoYZ7Au8yUqebgiBUDtw2evW9EoUoWl8oIXehEF70C4j-py5iVjOmYPSe71aIyLwllWQnhKErK2Qc8LUqOeoAQI6UyM1x1SNLct1x5_XlsgzLPG6LhLPd3Psc7n8cpfHmHHLeHLZ0Ay58OeNeAkoOrxPdfsjKLq1Xe7ccZzJDhs32fHgzMGMyy0w554YBsT9tYQIfwNYjbHVCqfX1LNZ1YyXZMVIDpv9o65mvyIDxEb8hufXll3pL76kc9XV3ukx0-FvvecH8BadKyNQ |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Injectable+controlled+release+depots+for+large+molecules&rft.jtitle=Journal+of+controlled+release&rft.au=Schwendeman%2C+Steven+P&rft.au=Shah%2C+Ronak+B&rft.au=Bailey%2C+Brittany+A&rft.au=Schwendeman%2C+Anna+S&rft.date=2014-09-28&rft.eissn=1873-4995&rft.volume=190&rft.spage=240&rft_id=info:doi/10.1016%2Fj.jconrel.2014.05.057&rft_id=info%3Apmid%2F24929039&rft.externalDocID=24929039 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-3659&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-3659&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-3659&client=summon |